[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578534":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":58,"collaborators":62,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":18,"enrollmentInfo":77,"targetDuration":18,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":91,"whyStopped":18,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Chongqing Emergency Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vericiguat Treatment Group","EXPERIMENTAL","Patients enrolled in the experimental group will receive 26 weeks of oral vericiguat on top of the standard treatment, with vericiguat at a dose of 2.5 mg once a day, doubled every fortnight to a maximum dose of 10 mg once a day at the end of week 6 of the visit, which will be maintained for the duration of the treatment.",[13],"Drug: Vericiguat",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Treatment Group","NO_INTERVENTION","Patients enrolled in the controlled group will receive 26 weeks of standard heart failure and coronary heart disease treatment",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Vericiguat",[9],[25],"BAY1021189",[27],{"name":28,"affiliation":29,"role":30},"Dongying Zhang, Professor","Chongqing Central Hospital of Chongqing University, Chongqing Emergency Medical Center","STUDY_CHAIR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","86-13608398395","zhangdongying@cqu.edu.cn",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Junlong Chen, M.D.","86-15111871817","junlongchen2024@163.com",[41],{"facility":42,"status":18,"city":43,"state":18,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"The First Affiliated Hospital of Chongqing Medical University","Chongqing","400000","China","CN",{"type":48,"coordinates":49},"Point",[50,51],106.55771,29.56026,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":18,"email":57},"Lei Gao, M.D.","86-15123908507","653161583@qq.com",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Dongying Zhang","Professor",[63,65],{"name":64,"class":6},"The Second Affiliated Hospital of Chongqing Medical University",{"name":66,"class":67},"The First Affiliated Hospital of Chongqing Medical Universty","UNKNOWN","100578534","phase-4-efficacy-and-safety-of-early-initiation-of-vericiguat-in-heart-failure-after-acute-myocardial-infarction-100578534",false,"NCT06812546","Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction","VIC-MI","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Undertaking revascularization for criminal coronary artery during hospitalization\n* Acute heart failure occurs within 14 days in hospital after STEMI or NSTEMI, meeting all of the following criteria: typical symptoms or signs of heart failure; Treatment with oral or intravenous diuretics is required; LVEF measured by echocardiography is ≤ 45%; Elevated levels of NT proBNP in patients with sinus rhythm ≥ 1000pg\u002Fml and atrial fibrillation\u002Fflutter ≥ 1600pg\u002Fml\n* eGFR ≥ 15 ml\u002Fmin\u002F1.73m2\n* Informed consent has to be given in written form\n\nExclusion Criteria:\n\n* Plan to undergo staged revascularization or if the criminal coronary artery has not been successfully opened\n* Severe and uncontrolled lung diseases, such as newly developed pulmonary embolism, primary pulmonary hypertension, acute exacerbation of COPD, etc\n* Severe liver and kidney dysfunction, Child Pugh grade C or eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2\n* Allergies to ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA, Vericiguat, and other medications\n* Symptomatic hypotension or systolic blood pressure less than 90mmHg after discontinuing intravenous medication\n* Women in the perinatal period or those planning to conceive\n* Patients planning to undergo elective surgical treatment or tumor chemotherapy\n* Diagnosed as Takotsubo cardiomyopathy or nonobstructive acute myocardial infarction (MINOCA)\n* Previous diagnosis of cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, etc.\n* Autoimmune disease or infectious diseases with typical cardiovascular damage, such as syphilis, systemic lupus erythematosus, etc.\n* Diagnosed with severe heart valve disease","ALL","18 Years",{"count":78,"type":79},200,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.",[85,86,87],"Heart Failure","Acute Myocardial Infarction (AMI)","Acute Heart Failure (AHF)",[22,89,85,90],"Guideline-Directed Medical Therapy","Acute myocardial infarction","NOT_YET_RECRUITING","2025-02-02",{"date":94,"type":95},"2025-02-06","ACTUAL",{"date":97,"type":79},"2025-04-01",{"date":99,"type":79},"2026-12-30",{"name":60,"class":6},1]